Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × brilacidin × Other × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other 1 Head & Neck 1

Conditions

Stomatitis 1 Mucositis 1 Head and Neck Neoplasms 1

Interventions

naloxegol 7 alvimopan 6 Radiotherapy 4 tegaserod 3 angiotensin I (1-7) 3 Injections 3 Cisplatin 3 RRx-001 2 tempol 1 prucalopride 1 oxycodone naloxone combination 1 naldemedine 1 methylnaltrexone 1 linaclotide 1 licogliflozin 1 hydrated silica gel-based toothpaste 1 brilacidin 1 apraglutide 1 aluminum hydroxide, magnesium hydroxide, drug combination 1 Xylitol 1 Water 1 Therapeutics 1 Testosterone Propionate 1 Robotic Surgical Procedures 1 Radiotherapy, Intensity-Modulated 1 Phenylephrine 1 Oxycodone 1 Naloxone 1 Lubiprostone 1 Lidocaine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02324335 2019-01-16

Brilacidin

Innovation Pharmaceuticals, Inc.

Phase 2 Completed

61 enrolled 12 charts

Head & NeckOther

Head and Neck Neoplasms, Stomatitis, Mucositis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡